Here are relevant reports on : prostate-cancer-diagnostics-market
-
Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region - Global Forecast to 2029
The global fusion biopsy market, valued at US$0.61 billion in 2023, stood at US$0.65 billion in 2024 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2029, culminating in a forecasted valuation of US$0.91 billion by the end of the period. Some main drivers for the growth of the fusion biopsy market are the growing prevalence of prostate cancer, since it's among one of the most common serious health concerns for males on a global scale.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035
The global radioligand therapy market, valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.2% from 2025 to 2035, culminating in a forecasted valuation of US$10.91 billion by the end of the period. The growth of this market is primarily attributed to factors such as increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, and the rising adoption of PSMA and SSTR PET imaging for patient selection.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
European NGS Services Market by Technology (SBS, SBL, SMRT, Pyrosequencing), Application (Exome Sequencing, CHIP-Seq), End User (Pharmaceutical Companies, Hospital), Disease [Oncology (Prostate, Lung, & Breast Cancer), Rare Diseases) - Forecast to 2020
The NGS services market in Europe is expected to reach USD 1,152 Million by 2020 from USD 444 Million in 2015, at a CAGR of 21% from 2015 to 2020. Factors such as rising preference of NGS over other platforms; rapid and cost-efficient sequencing; rising prevalence of inherited diseases; application of genomics in drug discovery; growing prevalence of cancer and other malignant diseases; and partnerships among companies, R&D centers, and universities are expected to drive market growth. However, high dependence on grants for R&D, lack of analytics, and stringent reimbursement policies are likely to restrict the growth of this market to a certain extent.
- Published: October 2015
- Price: $ 4950
- TOC Available:
-
Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028
The global particle therapy market, valued at US$0.6 billion in 2022, stood at US$0.7 billion in 2023 and is projected to advance at a resilient CAGR of 8.2% from 2023 to 2028, culminating in a forecasted valuation of US$1.1 billion by the end of the period. Many factors, such as technological advancements, funding and reimbursement, strong healthcare funding, active research funding, a clear regulatory framework, growing minimally invasive procedure adoption, and the presence of key market players in developing regions are driving the growth of the particle therapy market
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032
The global cancer vaccines market, valued at US$9.70 billion in 2023, stood at US$9.84 billion in 2024 and is projected to advance at a resilient CAGR of 5.4% from 2024 to 2032, culminating in a forecasted valuation of US$15.00 billion by the end of the period. The cancer vaccines market is growing rapidly, fueled by rising prevalence of cancer, technological advancements in immunotherapy, and increasing adoption of preventive healthcare across the globe.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028
The global theranostics market, valued at US$1.9 billion in 2022, stood at US$2.1 billion in 2023 and is projected to advance at a resilient CAGR of 15.5% from 2023 to 2028, culminating in a forecasted valuation of US$4.3 billion by the end of the period. Increasing establishment of hospitals, rising focus on targeted therapies, and introduction of novel theranostic approaches are expected to drive the market during the forecast period.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030
The global immunohistochemistry market, valued at US$3.31 billion in 2024, stood at US$3.55 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a forecasted valuation of US$5.14 billion by the end of the period. The increasing number of cancer cases is one of the key factors driving the uptake of IHC products, which, in turn, leads to a greater need for accurate and efficient diagnostic tools such as IHC tests.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Womens Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care) & Region - Global Forecast to 2025
The global womens health diagnostics market growth is primed to transition from $25.0 billion in 2020 to $36.6 billion by 2025, showcasing a strong CAGR of 7.9%. The market growth is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
C – Reactive Protein Testing Market by Assay Type (ELISA, Turbidimetric, Immunoturbidimetric), Application (Cardiovascular, Inflammatory Disease, Rheumatoid Arthritis, Cancer), End User (Hospitals, Clinics, Diagnostics Labs) - Global Forecast to 2023
The Global C-Reactive Protein Testing market is expected to reach USD 1.75 billion by 2023 from USD 1.62 billion in 2018, growing at a CAGR of 1.5 % from 2018 to 2023. Growing occurrences of Non Communicable Diseases (NCDs) such as Cardiovascular Diseases, Diabetes and other inflammatory diseases are the major drivers for this market. Point of Care technology for CRP testing is also being used for diagnostic purposes.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024
The Lymphedema Diagnostics Market is expected to grow from USD 24 million in 2019 to USD 35 million by 2024, at a CAGR of 7.4% during the forecast period. The major players operating in the lymphedema diagnostics market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).
- Published: October 2019
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
